Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Jul 10, 2026
Invesco S&P International Developed Quality ETF (IDHQ): Quality Focus in Developed Markets Outside the U.S.

Invesco S&P International Developed Quality ETF (IDHQ): Quality Focus in Developed Markets Outside the U.S.

Key Takeaways

  • Global economic growth expectations and interest rate trajectories in developed economies outside the U.S. represent key macro drivers for international quality equities.
  • Sector outlooks in technology, healthcare, and industrials could shape performance given the ETF’s emphasis on high-quality companies with strong return-on-equity profiles.
  • Portfolio exposure to large- and mid-cap developed-market stocks offers potential resilience through quality screening but carries geographic concentration risks in Europe and Japan.
  • ETF inflow trends and broader international equity demand may influence assets under management (AUM) as investors seek diversified non-U.S. exposure.
  • Upcoming catalysts include central bank policy decisions, corporate earnings seasons, and index rebalancing events that could affect constituent weights.
  • Structural strengths include a rules-based focus on financial quality metrics, supporting long-term positioning amid evolving market cycles.

Portfolio Exposure and ETF Strategy Overview

The IDHQ tracks the S&P Quality Developed ex-U.S. LargeMidCap Index. This index selects constituents from the S&P Developed ex-U.S. LargeMidCap Index based on a quality score derived from return on equity, accruals ratio, and financial leverage ratio. The ETF employs a passive strategy, investing at least 90% of its assets in the index’s common stocks, with semi-annual rebalancing and reconstitution.

Top holdings typically include companies such as ASML Holding NV, Roche Holding AG, and Novartis AG, with significant allocations to industrials, technology, and healthcare sectors. Geographic exposure concentrates in Europe and Japan, reflecting developed-market opportunities outside the United States. This positioning structurally favors firms demonstrating consistent profitability and prudent financial management, potentially supporting performance through economic cycles by emphasizing balance-sheet strength and earnings quality. I also checked this using Tickeron’s AI Screener to see how the holdings compare within the broader international quality space.

Major Catalysts Ahead

Interest rate decisions by the European Central Bank and Bank of Japan could affect valuations of quality-oriented international equities, as lower rates often support growth-sensitive sectors within the ETF’s holdings. Inflation trends in Europe and Asia may influence corporate margins and investor sentiment toward developed-market equities.

Earnings outlooks for major holdings in technology and healthcare will remain important, given their weight in the portfolio and sensitivity to global supply chains and innovation cycles. Policy or regulatory developments, such as trade agreements or tax reforms in key regions, could alter competitive dynamics for multinational constituents. ETF inflows or outflows, driven by investor appetite for international diversification, may also impact liquidity and AUM growth.

Sector, Index, and Macroeconomic Outlook

Broader equity market trends in developed regions outside the U.S. hinge on synchronized global growth, currency movements, and monetary policy divergence. Lower interest rates or accommodative stances could benefit quality stocks by reducing borrowing costs and supporting valuations in capital-intensive sectors like technology and industrials.

Inflation moderation may ease pressure on input costs for healthcare and consumer defensive companies within the index. Economic growth expectations in Europe and Japan, alongside equity market breadth, will likely influence the underlying S&P Quality Developed ex-U.S. LargeMidCap Index. Commodity cycles and global supply-chain stability could further affect industrials exposure, while currency fluctuations add an additional layer of sensitivity for U.S.-based investors in this international allocation.

Using the Trend Prediction Engine for Market Insights

In my research process, Tickeron’s Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality. I find it useful when assessing potential movements in international ETFs like this one, as it adds another layer of data-driven perspective to the fundamental outlook.

Long-Term Outlook and Structural Trends

Long-term sector growth in technology and healthcare, driven by innovation adoption and demographic shifts toward aging populations in developed markets, aligns with the ETF’s quality focus. Economic cycles and interest rate normalization could favor companies with strong balance sheets and consistent profitability metrics emphasized by the index methodology.

Global investment trends toward international diversification may support demand for developed ex-U.S. equities, while market structure changes such as evolving ESG considerations or regulatory frameworks could influence index composition over time. The underlying index’s emphasis on high-quality large- and mid-cap firms positions the ETF to capture structural opportunities in stable, cash-generative businesses across Europe, Japan, and other developed regions. From what I see, this rules-based approach remains a steady way to gain exposure without chasing short-term noise.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IDHQ

Contributor

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.


Momentum Indicator for IDHQ turns positive, indicating new upward trend

IDHQ saw its Momentum Indicator move above the 0 level on July 30, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned positive. In of the 79 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for IDHQ just turned positive on July 31, 2026. Looking at past instances where IDHQ's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IDHQ advanced for three days, in of 314 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDHQ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IDHQ broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are AstraZeneca PLC (NYSE:AZN), BHP Group Limited (NYSE:BHP), Boeing Company (NYSE:BA), Spotify Technology SA (NYSE:SPOT), Canadian Natural Resources Limited (NYSE:CNQ), Suncor Energy (NYSE:SU), Archer Daniels Midland Company (NYSE:ADM).

Industry description

The investment seeks to track the investment results (before fees and expenses) of the S&P Quality Developed ex-U.S. LargeMidCap Index (the "underlying index"). The fund will invest at least 90% of its total assets in securities that comprise the underlying index. The index provider compiles, maintains and calculates the underlying index, which is composed of constituents of the S&P Developed ex-U.S. LargeMidCap Index that the index provider identifies as being of the highest quality-that is, stocks of companies that seek to generate higher revenue and cash flow than their counterparts through prudent use of assets and finances.

Market Cap

The average market capitalization across the Invesco S&P International Dev Qual ETF ETF is 57.38B. The market cap for tickers in the group ranges from 989.57K to 663.18B. ASML holds the highest valuation in this group at 663.18B. The lowest valued company is ANDR at 989.57K.

High and low price notable news

The average weekly price growth across all stocks in the Invesco S&P International Dev Qual ETF ETF was 33%. For the same ETF, the average monthly price growth was 31%, and the average quarterly price growth was 495%. REA experienced the highest price growth at 22%, while AGL experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the Invesco S&P International Dev Qual ETF ETF was 7%. For the same stocks of the ETF, the average monthly volume growth was 17% and the average quarterly volume growth was -25%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 46
P/E Growth Rating: 55
Price Growth Rating: 50
SMR Rating: 60
Profit Risk Rating: 61
Seasonality Score: -38 (-100 ... +100)
View a ticker or compare two or three
IDHQ
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category ForeignLargeGrowth

Profile
Details
Category
Foreign Large Growth
Address
PowerShares Exchange-Traded Fund Tr II301 West Roosevelt RoadWheaton
Phone
N/A
Web
www.invescopowershares.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.